Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing therapies that target Natural Killer T (NKT) cells for the treatment of inflammatory, fibrotic and autoimmune diseases. This news page aggregates company announcements, clinical updates and capital markets disclosures related to GRI Bio and the GRI stock.
Investors following GRI Bio’s news can track the progress of its lead program GRI-0621, an oral RARβγ agonist and iNKT activity inhibitor being developed for idiopathic pulmonary fibrosis (IPF). The company has reported interim and topline results from a Phase 2a randomized, double-blind, placebo-controlled trial in IPF, including safety and tolerability data, changes in collagen turnover biomarkers, signals of alveolar basement membrane repair and analyses of forced vital capacity (FVC). Additional releases describe immune profiling data showing iNKT inhibition and shifts toward an anti-fibrotic cytokine profile.
News items also cover interim biomarker and lung function analyses, recommendations from the Independent Data Monitoring Committee, and presentations at investor and industry conferences. These communications provide context on how GRI Bio interprets emerging clinical data and its plans for further development of GRI-0621.
Beyond clinical results, GRI Bio issues press releases on financing transactions, such as its December 2025 best efforts public offering of common stock, pre-funded warrants and Series F warrants, and related Nasdaq listing compliance updates. Governance and corporate actions, including equity incentive plan amendments and annual meeting matters, are reflected in associated SEC filings and news references.
By reviewing this GRI news feed, readers can monitor key developments in GRI Bio’s NKT cell–modulating pipeline, particularly in IPF and systemic lupus erythematosus, as well as follow capital raising activities and other material events that may be relevant to GRI stock research. Bookmark this page to access an organized stream of GRI Bio press releases and related market updates.
GRI Bio, Inc. (NASDAQ: GRI) has appointed Leanne Kelly as Chief Financial Officer. With over 20 years of experience in finance, particularly in life sciences and technology, Kelly previously held the CFO role at Vallon Pharmaceuticals, which recently merged with GRI Bio. Her expertise in public and private markets was deemed essential as GRI transitions post-merger.
CEO Marc Hertz expressed confidence in Kelly's capabilities to strengthen the company's financial position and presence in the investment community. GRI Bio focuses on innovative therapies targeting inflammatory and autoimmune diseases, with promising developments like GRI-0621 for idiopathic pulmonary fibrosis.
GRI Bio, Inc. (NASDAQ: GRI) has announced significant advancements following its merger with Vallon Pharmaceuticals, effective April 24, 2023. The company has appointed three industry veterans—David Szekeres as Chairman, Roelof Rongen, and Camilla V. Simpson—to its Board of Directors, marking a pivotal transformation.
GRI Bio focuses on developing Natural Killer T (NKT) cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. Their lead program, GRI-0621, aims to treat idiopathic pulmonary fibrosis, a condition with critical unmet needs. With a library of over 500 proprietary compounds, GRI is well-positioned for future growth in the biopharmaceutical market.